Key Highlights
- FDA advisory committee rejected AstraZeneca’s camizestrant for breast cancer treatment with a 6-3 vote
- Truqap for prostate cancer received positive 7-1 recommendation from separate FDA panel
- Shares of AZN declined 1.13% to $185.25 in premarket trading
- Analysts at Morgan Stanley cite “regulatory overhang” concerns following camizestrant decision
- Company maintains confidence in camizestrant clinical data despite advisory panel outcome
AstraZeneca experienced contrasting outcomes from FDA advisory committees on Thursday, as evaluations of two oncology medications yielded opposing recommendations.
Shares declined 1.13% during premarket trading on Friday, trading at $185.25. The stock has fallen approximately 6.9% over the last month, underperforming the S&P 500’s 9.9% gain during the same timeframe.
The Oncologic Drugs Advisory Committee (ODAC) of the FDA examined two separate cancer therapies from AstraZeneca during a single session — delivering starkly different recommendations.
On the disappointing end, committee members rejected camizestrant by a 6-3 margin, an oral medication designed for first-line treatment of HR-positive, HER2-negative advanced breast cancer patients carrying ESR1 mutations.
Panel members concluded that camizestrant failed to demonstrate a “meaningful benefit” for patients whose cancer hadn’t already advanced beyond initial therapies.
Data from the SERENA-6 clinical trial demonstrated that camizestrant produced a 56% decrease in disease advancement or patient mortality. Those receiving the treatment experienced a median progression-free period of 16 months, versus 9.2 months for patients on current standard treatments.
However, committee members expressed reservations regarding the completeness of critical secondary endpoints, such as overall survival metrics and time until second disease progression, based on interim analysis data available.
A subsequent pre-scheduled analysis revealed statistically significant PFS2 improvement — 25.7 months compared to 19.1 months — with overall survival data continuing to favor camizestrant.
AstraZeneca expressed disappointment with the panel’s decision while maintaining confidence in the clinical evidence and therapeutic value for patients.
Wall Street Analysts Express Regulatory Concerns
Morgan Stanley research team, headed by Sarita Kapila, described the outcome as creating “regulatory overhang and a dent to investor sentiment.”
The analysts acknowledged that FDA approval remains within possibility, though the 6-3 vote diminishes prospects for the SERENA-6 indication. While the FDA isn’t obligated to align with advisory committee recommendations, it generally follows their guidance. The agency’s final determination is pending.
Prostate Cancer Treatment Receives Favorable Committee Review
The day brought positive developments as well. ODAC members endorsed Truqap (capivasertib) with a 7-1 vote for use alongside abiraterone and androgen deprivation therapy in treating patients with PTEN-deficient metastatic hormone-sensitive prostate cancer.
This recommendation stemmed from Phase 3 CAPItello-281 trial findings, demonstrating a 19% reduction in disease progression or mortality risk.
Median radiographic progression-free survival extended to 33.2 months among Truqap recipients, exceeding the control group’s 25.7 months.
Additional endpoints similarly supported the combination therapy, including delayed progression toward castration resistance and enhanced PSA marker improvements.
The safety data aligned with established knowledge of these treatments, although Grade 3 or higher adverse reactions occurred more frequently with Truqap. Overall survival information continues developing but indicates favorable trends for the combination approach.
AZN shares remain essentially flat for the year, while the S&P 500 has climbed 4.8% during the identical timeframe.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
